Real-world COMPETE SWITCH CV data at EASD 2026 linked semaglutide 2 mg escalation to 6% lower MACE risk vs switching to tirzepatide in T2D.
News|Articles|September 29, 2026
Heart Failure Society of America 2026 Preview: 6 Trials to Watch
Author(s)Ryan Livingston
Fact checked by: Abigail Brooks, MA
Get a head start on one of the biggest heart failure conferences of the year with our HFSA 2026 preview.
Advertisement
Advertisement
The
Related to this article
Higher levels of Lp(a) are also associated with deep vein thrombosis and pulmonary embolism according to this retrospective cohort study.
Donald Cutlip, MD, discusses the sirolimus balloon’s approval and its role in clinical practice for patients with ISR.
Manju Dawkins, MD, discusses Skin Angels, why clinicians belong in dermatology innovation, and her work to reduce injection pain and needle anxiety.
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.
Smoking was associated with greater odds of EPI, and prevalence ranged from 21.1% to 52.1% depending on the diagnostic test used.
Advertisement
Advertisement